Edesa Biotech (EDSA) has had the highest return since January 1, 2026 by a US stock in the Biotechnology Industry, returning 907.6%.
| ASSET | % RETURN |
|---|---|
Edesa Biotech (EDSA) | 907.59% |
Adlai Nortye Ltd American Depositary Shares (ANL) | 876.06% |
AN2 Therapeutics (ANTX) | 314.29% |
Immunitybio (IBRX) | 303.47% |
Sutro Biopharma (STRO) | 234.09% |
TuHURA Biosciences (HURA) | 225.97% |
Zentalis Pharmaceuticals Llc (ZNTL) | 202.96% |
XWELL (XWEL) | 187.5% |
Tango Therapeutics (TNGX) | 181.02% |
Erasca (ERAS) | 179.51% |
Climb Bio (CLYM) | 176.34% |
Cue Biopharma (CUE) | 173.07% |
MacroGenics (MGNX) | 158.39% |
Rallybio (RLYB) | 157.43% |
Eledon Pharmaceuticals (ELDN) | 153.21% |
Alumis (ALMS) | 152.1% |
Cyclerion Therapeutics (CYCN) | 147.2% |
Moolec Science SA Ordinary Shares (MLEC) | 146.87% |
Artiva Biotherapeutics, Inc Common Stock (ARTV) | 146.65% |
Century Therapeutics (IPSC) | 145.36% |
Akanda (AKAN) | 145.13% |
Nanobiotix (NBTX) | 142.49% |
Day One Biopharmaceuticals (DAWN) | 131.75% |
InflaRx (IFRX) | 131.07% |
Spyre Therapeutics (SYRE) | 130.92% |